Tuesday, February 9th, 2016

Type 2 Diabetes Mellitus Therapeutics in Asia-Pacific Markets to 2021 - Increasing Usage of Newer Therapies and Expanding Treatment Population to Encourage Robust Growth

WiseGuyReports.com adds “Type 2 Diabetes Mellitus Therapeutics in Asia-Pacific Markets to 2021 - Increasing Usage of Newer Therapies and Expanding Treatment Population to Encourage Robust Growth” to its research database.

Type 2 Diabetes Mellitus Therapeutics in Asia-Pacific Markets to 2021 - Increasing Usage of Newer Therapies and Expanding Treatment Population to Encourage Robust Growth


Diabetes mellitus is a group of metabolic diseases characterized by chronic hyperglycemia - high blood glucose levels - that results from defects in insulin secretion, insulin action, or a combination of these. This chronic hyperglycemia is associated with long-term damage, dysfunction and failure of multiple organs including the eyes, kidneys, nerves, heart and blood vessels. The vast majority of diabetes mellitus patients can be classified as having either Type 1 Diabetes Mellitus (T1DM) or Type 2 Diabetes Mellitus (T2DM). Approximately 85-95% of all diabetics have T2DM.

T2DM treatment has been revolutionized in the past decade, especially with the increased use of new therapies. The marketed products landscape comprises a wide range of treatment options, including biguanide (metformin), sulfonylureas, thiazolidinediones, GLP-1 receptor agonist, DPP-4 inhibitor, SGLT-2 inhibitor, and insulin therapies. Nevertheless, significant unmet need remains for products that can offer better glycemic control as well as the prevention and cure of diabetic complications, such as diabetic nephropathy, retinopathy, and cardiovascular disease.

Complete report details @ https://www.wiseguyreports.com/reports/type-2-diabetes-mellitus-therapeutics-in-asia-pacific-markets-to-2021-increasing-usage-of-newer-therapies-and-expanding-treatment-population-to-encourage-robust-growth


The current T2DM in the Asia-Pacific (APAC) market contains novel products, including Jardiance - a SGLT-2 inhibitor; Victoza - a GLP-1 receptor agonist; and Galvus - a DPP-4 inhibitor. 
- What are the competitive advantages of the existing novel drugs? 
With over 500 active pipeline molecules, most of the late-stage investigational drug candidates are being evaluated, featuring improved dosing regimens and administration routes, in comparison to currently marketed products and combination therapies. 
- Which classes of novel drugs are most prominent within the pipeline? 
- Is there strong potential for the pipeline to address unmet needs within the T2DM market? 
Analysis of clinical trials, since 2006, identified that the failure rates of T2DM molecules were highest in Phase II, at 54%, with the overall attrition rate for T2DM at 82.6%. 
- How do failure rates vary by product stage of development, molecule type, and mechanism of action? 
- How do other factors, such as average trial duration and trial size influence the costs and risks associated with product development? 
Over the 2014-2021 forecast period, the T2DM therapeutics in the APAC markets is expected to increase in value at a CAGR of 7.7%, from $6.07 billion to over $10.2 billion. 
- Which markets make the most significant contribution to the current market size? 
- What are the epidemiology trends in these markets? 
- Will new market entrants lead to substantial changes in annual therapy costs? 
- How will different treatment usage patterns impact growth in the four assessed Asia-Pacific markets? 
Rising T2DM prevalence and the uptake of newer therapies will lead to significant market growth, over the forecast period, despite generic sales erosion resulting from patent expirations. 
- Will patent expirations or emerging pipeline molecules threaten the commercial success of existing drugs? 
- Which patent expirations will have the most significant impact on the market?

Reasons to buy

This report will enable you to - 
- Understand the clinical context of T2DM by considering symptoms, etiology, pathophysiology, epidemiology, diagnosis, and treatment options. 
- Identify the therapeutic strategies, products, and companies that dominate the current marketed products landscape and recognize gaps and areas of unmet need. 
- Identify key pipeline trends in molecule type, administration route, mechanism of action, and novelty. 
- Consider market opportunities and potential risks by examining trends in T2DM clinical trial size, duration, and failure rate by stage of development, molecule type, and mechanism of action. 
- Recognize the late-stage pipeline molecules that have demonstrated strong therapeutic potential in T2DM by examining clinical trial data and multi-scenario product forecast projections. 
- Compare treatment usage patterns, annual therapy costs, and market growth projections for China, India, Australia, and Japan. 
- Discover trends in licensing and co-development deals concerning T2DM products and identify the major strategic consolidations that have shaped the commercial landscape.

Order a Purchase Report Copy @ https://www.wiseguyreports.com/checkout?currency=one_user-USD&report_id=337196       

Table Of Content           

1.1 List of Tables 6 
    1.2 List of Figures 7 
2 Introduction 9 
    2.1 Disease Overview 9 
    2.2 Classification 9 
    2.3 Symptoms 10 
    2.4 Etiology 10 
    2.5 Pathophysiology 11 
    2.6 Epidemiology 13 
    2.7 Prognosis 13 
    2.8 Co-morbidities and Complications 14 
    2.9 Diagnosis 15 
    2.10 Assessing Treatment Effectiveness 17 
    2.11 Treatment 17 
      2.11.1 Non-insulin T2DM Therapies 19 
      2.11.2 Insulin T2DM Therapies 22 
    2.12 Treatment Segments 24 
      2.12.1 Non-insulin therapies 24 
      2.12.2 Insulin Therapies 39 
3 Marketed Products 43 
    3.1 Overview 43 
    3.2 Biguanides 44 
      3.2.1 Metformin 44 
    3.3 Sulfonylureas 45 
    3.4 Thiazolidinediones 47 
      3.4.1 Pioglitazone 47 
    3.5 GLP-1 receptor agonists 48 
      3.5.1 Byetta (exenatide) 48 
      3.5.2 Bydureon (exenatide) 49 
      3.5.3 Victoza (liraglutide) 50 
      3.5.4 Lyxumia (lixisenatide) 51 
      3.5.5 Tanzeum (albiglutide) 53 
      3.5.6 Trulicity (dulaglutide) 54 

Sample Page of report @  https://www.wiseguyreports.com/sample_request/type-2-diabetes-mellitus-therapeutics-in-asia-pacific-markets-to-2021-increasing-usage-of-newer-therapies-and-expanding-treatment-population-to-encourage-robust-growth

Contact Profile


Wise Guy Reports is part of the Wise Guy Consultants Pvt. Ltd. and offers premium progressive statistical surveying, market research reports, analysis & forecast data for industries and governments around the globe.

Wise Guy Reports understand how essential statistical surveying information is for your organization or association. Therefore, we have associated with the top publishers and research firms all specialized in specific domains, ensuring you will receive the most reliable and up to date research data available. We also provide COTS (Commercial off the Shelf) business sector reports as custom exploration agreeing your particular needs.

Our Market Research Reports and Consulting Services 

Wise Guy Reports features an exhaustive list of market research reports from hundreds of publishers worldwide. We boast a database spanning virtually every market category and an even more comprehensive collection of market research reports under these categories and sub-categories. The Wise Guy Reports team prides itself in being the chosen source for market research reports, report customizations services, and other ancillary services such as a Newsletter service and corporate service for large organizations.

Hundreds of large and small organizations across virtually every industry sector worldwide are currently reaping rich dividends from the sharp insights provided by market research reports sourced through Wise Guy Reports. 

Gaining an insight into emerging trends, opportunities and potential threats is key to long-term sustenance in a competitive environment. The handpicked collection of market research reports on Wise Guy Reports is centred on this proven principle.

Norah Trent
P: +44 208 133 9349
M: +1 646 845 9349
W: www.wiseguyreports.com/


Mellitus Therapeutics , Mellitus Therapeutics Industry,Mellitus Therapeutics Market,Mellitus Therapeutics Market Trends, Mellitus Therapeutics Industry Trends, Mellitus Therapeutics Market Share,Mellitus Therapeutics Market Growth,Mellitus Therapeut




More Formats

View QR Code